Myonex ApS: Financial statements 2023
CVR: 39905094
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Myonex ApS (CVR 39905094) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR 2,653,832 and a net result of EUR 1,909,497 compared with EUR 8,755,907 the year before. That is a decrease of 76.7% compared with the year before. Equity in the 2023 report amounted to EUR 16,780,504. The solvency ratio was 84.3%.
- Gross Profit
- EUR 2,653,832
- Profit/Loss
- EUR 1,909,497
- Equity
- EUR 16,780,504
- Total Assets
- EUR 19,908,179
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 2.7M EUR | 1.9M EUR | 16.8M EUR | - |
| 2022 | - | 11.4M EUR | 8.8M EUR | 14.9M EUR | - |
| 2021 | - | 8.1B EUR | 6.2B EUR | 6.1B EUR | - |
| 2020 | - | -104K EUR | -105K EUR | -179K EUR | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Myonex ApS has published its annual report for 2022. Gross profit came to DKK 11,411,359, and the net result was DKK 8,755,907.
About Myonex ApS
Myonex ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Myoderm ApS. The management consists of Gregory Thomas Lavin and Michael Allen Cohen. The company is owned by Myonex, LLC. In 2025, the company reported a gross profit of EUR 1,009,020 and a net result of EUR 580,466 compared with EUR 2,155,499 the year before. Equity in the 2025 report amounted to EUR 19,516,469.